跳至主要内容
临床试验/NCT00432198
NCT00432198已完成4 期

Zolpidem Postmarketing Clinical Study: A Double Blind, Placebo Controlled Group Comparative Trial in the Adolescent Patients With Insomnia

Astellas Pharma Inc0 个研究点目标入组 122 人开始时间: 2007年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
122
主要终点
Mean daily sleep latency for double-blind period

研究概览

简要总结

To investigate the efficacy and safety of zolpidem for pediatric insomniacs in a randomized double blind-controlled trial

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • patients diagnosed as having nonorganic insomnia of nonorganic sleep disorder in ICD10
  • patients whose age at the time of obtaining consent is 12 years or over and 18 years or below

排除标准

  • patients with schizophrenia or manic-depressive illness
  • patients with insomnia caused by physical diseases
  • patients having a history of hypersensitivity to zolpidem
  • patients with attention-deficit hyperactivity disorder

研究组 & 干预措施

1

Experimental

Oral

干预措施: Zolpidem (Myslee®) (Drug)

2

Experimental

Oral

干预措施: Zolpidem (Myslee®) (Drug)

3

Placebo Comparator

Oral

干预措施: placebo (Drug)

结局指标

主要结局

Mean daily sleep latency for double-blind period

时间窗: 2 Weeks

次要结局

  • Impression of patient for double-blind period(2 Weeks)
  • Mean daily time of intermediate awaking(2 Weeks)
  • Mean daily total hours of sleep(2 Weeks)
  • Mean daily frequency of intermediate awaking(2 Weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验